Krishna Gupta
Founder of REMUS Capital
Krishna Gupta
Founder of REMUS Capital
Greater Boston
Overview
Work Experience
Founder & CEO
2008 - Current
We're looking for the rebels. REMUS is a VC firm that leads Pre-Seed, Seed, and Series A rounds in Applied AI and Healthcare companies. We have a concentrated investment approach and focus on Building, not Betting. We admire people who think really big. Those who want to craft legendary, contrarian companies that can be worth $5B or more. We are patient, with youth and experience on our side. I founded the firm out of an MIT dorm in 2008, amidst the Great Recession. I've raised over $200M and we've proved ourselves to be exceptional partners across a decade. We are always there in the trenches with you and have brought many million-dollar customers to our companies. I sit on the boards of Aila, Allurion, Ceres Imaging, Cogito, Cohealo, Humanyze, PetaGene, Placester, Presto, Vyome Biosciences, and ZeroCater - we've been the first institutional investor in each. I've also led our investments into ClassPass, Bombfell, Disruptor Beam, Gyft (acquired: First Data), Crocodoc (acquired: Box), and SchoolMint (acquired: Hero K12). https://remuscap.com/team-member/krishna-k-gupta/
Co-founder & ex-CEO
2017
Spun out of MIT and a YC alum, Presto Automation (Nasdaq: PRST) creates magical productivity technologies for restaurants, including a leading generative voice AI product solution that helps automate drive-thrus for some of the nation’s largest chains. While I was CEO, the stock 4Xed in price and 10Xed in volume, with Presto becoming part of the Russell 2000 index and being featured on Bloomberg TV, CNBC, the WSJ, and several other media outlets.
Chairman
2016
Leader in weight loss technology, spun out from Harvard (NYSE: $ALUR). I helped incubate Allurion's digital business leading to its conversational AI platform.
Chairman
2016
Leader in Vertical AI/analytics + embedded finance for agriculture, spun out from Stanford
Chairman
2018
Vyome is acting on a clear opportunity to leverage world-class Indian talent + cost arbitrage to tackle large US commercial opportunities in biotech and other related research-driven areas, at a time when US-India relations are on the rise. Its initial assets are targeting unmet immuno-inflammation diseases.
Board Member
2015
Leader in voice AI for call center applications, spun out from MIT
Board Member
2018
Leader in compression of genomic data, spun out of Cambridge
Co-Founder & Board Member
2013
Leader in AI for Organizational Health, spun out of MIT
Board Member
2019
Leader in Augmented Reality for industry
Board Member
2015
Leader in equipment sharing for hospitals